<DOC>
	<DOCNO>NCT01639690</DOCNO>
	<brief_summary>The patient inherit ß-thalassemia major gene . These gene mistake , body make normal red blood cell . Stem cell make bone marrow . They earliest form blood cell . This study do see investigator make stem cell produce normal red blood cell hemoglobin . The investigator collect stem cell . The gene mistake remove cell . These cell treat corrected gene make normal hemoglobin . These treated cell give back patient injection ( shot ) vein . This also know gene transfer . In order body accept cell , patient need receive low dose drug call busulfan . It drug prepare body receive new stem cell . This study let investigator know : - If safe give patient treat stem cell - If treat stem cell go bone marrow without cause side effect . Gene transfer use past five year . It successful treat many blood disorder . At least 20 patient receive type treatment patient get study . This treatment B-thalassemia major develop Memorial Sloan Kettering ( MSK ) . It study long time lab give patient .</brief_summary>
	<brief_title>ß-Thalassemia Major With Autologous CD34+ Hematopoietic Progenitor Cells Transduced With TNS9.3.55 Lentiviral Vector Encoding Normal Human ß-Globin Gene</brief_title>
	<detailed_description />
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>beta-Thalassemia</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Subjects must 18 year old Subjects may either gender ethnic background Subjects must confirm diagnosis ßthalassemia major enrolled hypertransfusion program confirm annual transfusion ≥100 mL/kg/yr &lt; 200 mL/kg/yr , AND ≥ 8 transfusion blood per year minimum two year . Patients must NOT HLAmatched sibling Patients must hydroxyurea ( HU ) erythropoietin ( EPO ) treatment least three month prior entry onto study Subjects must performance score Karnofsky ≥70 % time entry study . Subjects must liver iron value &lt; 15 mg/g/dry weight Iron quantitation may perform image T2*MRI biopsy Subjects must evidence cirrhosis** liver . Fibrosis liver test Fibroscan ( 47 , 48 , 49 ) , liver biopsy . These perform within approximately one year period prior entry onto study . Subjects evaluation cardiac function indicating : normal function MUGA scan ( Multiple Gated Acquisition scan ) methodology . And Patients must leave ventricular ejection fraction ( LVEF ) ≥ 60 % and/or T2*MRI cardiac evaluation T2* ≥20 milliseconds Subjects asymptomatic pulmonary function base Lung Diffusion Testing DLCO Test DLCO ≥ 50 % predict ( correct hemoglobin ) Subjects determination renal function base : serum creatinine &lt; = 1.5 mg/dL serum creatinine outside normal range , CrCl &gt; 60ml/min/1.73 m2 Subjects must adequate hepatic function base : &lt; 3 x ULN ALT &lt; 2.0 total serum bilirubin ( unless secondary hemolysis ) Patients must available followup evaluation 30 , 60 , 180 day post BMT yearly thereafter indefinitely . The possibility unrelated donor stem cell transplantation discuss patient , `` preliminary '' search unrelated donor may do request patient . However , find potential HLAmatched unrelated donor exclude patient participate trial ) . As inclusion criterion specific Lucarelli/Pesaro thalassemia pretransplant classification ( Class 1,2 3 accord presence absence fibrosis , adequate chelation and/or hepatomegaly ) , criterion state used lieu Lucarelli/Pesaro classification . Active infection include Hepatitis B Hepatitis C*** , Active infection include HTLV 1 2 , HIV 1 2 Patients treated HLTV HIV Diabetes Mellitus Bone Marrow myelodysplasia and/or chromosomal abnormality Female patient pregnant breast feeding Patients uncontrolled seizure disorder Patients severe pulmonary hypertension Tricuspid Jet velocity &gt; 2.5 m/sec Family history familial cancer syndrome ( leukemia , breast , ovarian , colorectal , etc . ) *** Definition active Hepatitis C include : Positive HCV RNA Viral load quantitative PCR testing Or Negative HCV RNA viral load BUT antiviral treatment Liver biopsy pathologic evidence Necrosis inflammation around portal area piecemeal necrosis interface hepatitis necrosis hepatocytes focal inflammation liver parenchyma . Inflammatory cell portal area ( `` portal inflammation '' ) . Fibrosis , early stage confine portal tract , intermediate stage expansion portal tract bridge portal area central area , late stage frank cirrhosis characterize architectural disruption liver fibrosis regeneration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>BUSULFAN</keyword>
	<keyword>G-CSF</keyword>
	<keyword>CliniMACS-CD34 Reagent System</keyword>
	<keyword>Blood transfusion</keyword>
	<keyword>10-164</keyword>
	<keyword>Autologous CD34+ cell transduce TNS9.3.55 , lentiviral vector encode human β-globin gene</keyword>
</DOC>